Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Seeking Alpha
Michael Metzger - CEO & Director Keith Goldan - CFO, Treasurer & Chief Accounting Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Presentation Etzer Darout Barclays Bank PLC, Research Division Hello, again, everyone. My name is Etzer Darout. I'm one of the Senior Biotech analysts at Barclays. It's my pleasure to have Syndax Pharmaceuticals with us for our next fireside chat. With me today, I have Michael Metzger, Chief Executive Officer; Keith Goldan, Chief Financial Officer; and Nick Botwood Chief Medical Officer. Thank you, gentlemen, for joining me. Maybe Michael, just to kick us off for those less familiar with the story, maybe just provide an overview of Syndax and then we can jump into Q&A. Michael Metzger CEO & Director Sure, happy to do so. Etzer, thank you for having us. Thank you to Barclays for kind invitation. Syndax is now a commerc
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals (SNDX) had its price target raised by JPMorgan Chase & Co. from $33.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- Syndax Pharmaceuticals (SNDX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SNDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.MarketBeat
- Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]Yahoo! Finance
SNDX
Earnings
- 2/26/26 - Miss
SNDX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- SNDX's page on the SEC website